MX2018005194A - Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. - Google Patents

Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.

Info

Publication number
MX2018005194A
MX2018005194A MX2018005194A MX2018005194A MX2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A MX 2018005194 A MX2018005194 A MX 2018005194A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
long
same
fusion proteins
fusion protein
Prior art date
Application number
MX2018005194A
Other languages
English (en)
Inventor
Hwan Kim Jun
LIM Seyoung
Seo Minji
Ho Choi Hyun
Kim Dohoon
Kyeong JU Mi
Young PARK Ju-
Hyun Choi Byung
Kyung Lee Jun
Gyun KIM Jong
Youn Nam Su
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2018005194A publication Critical patent/MX2018005194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención provee una proteí­na de fusión que comprende una proteí­na mutante de FGF21 y una región Fc de una inmunoglobulina. La proteí­na de fusión de conformidad con la presente invención presenta eficacia farmacológica, duración in vivo y estabilidad proteica mejoradas, y una composición farmacóutica que comprende la proteí­na de fusión como ingrediente activo se puede usar de manera efectiva como agente terapóutico para diabetes, obesidad, dislipidemia, sí­ndrome metabólico, enfermedad del hí­gado graso no alcohólico o esteatohepatitis no alcohólica.
MX2018005194A 2015-10-28 2016-10-28 Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. MX2018005194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150574A KR20170049319A (ko) 2015-10-28 2015-10-28 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012288 WO2017074117A1 (en) 2015-10-28 2016-10-28 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
MX2018005194A true MX2018005194A (es) 2018-07-06

Family

ID=58630685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005194A MX2018005194A (es) 2015-10-28 2016-10-28 Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.

Country Status (22)

Country Link
US (2) US11142557B2 (es)
EP (2) EP3368554B1 (es)
JP (2) JP7303629B2 (es)
KR (1) KR20170049319A (es)
CN (1) CN108290937B (es)
AU (2) AU2016346864B2 (es)
BR (1) BR112018008676A2 (es)
CA (1) CA3003109A1 (es)
CY (1) CY1123307T1 (es)
DK (1) DK3368554T3 (es)
ES (1) ES2815540T3 (es)
HK (1) HK1257375A1 (es)
HR (1) HRP20201392T1 (es)
HU (1) HUE051036T2 (es)
LT (1) LT3368554T (es)
MX (1) MX2018005194A (es)
PT (1) PT3368554T (es)
RS (1) RS60725B1 (es)
RU (1) RU2741087C2 (es)
SI (1) SI3368554T1 (es)
WO (1) WO2017074117A1 (es)
ZA (1) ZA201802002B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR20170049320A (ko) * 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
AU2017358289A1 (en) * 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EA201992516A1 (ru) * 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных
CN111050786A (zh) * 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
US20220064244A1 (en) * 2019-03-05 2022-03-03 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CA3136969A1 (en) * 2019-04-23 2020-10-29 Lg Chem, Ltd. Fusion polypeptide comprising fc region of immunoglobulin and gdf15
WO2021152396A1 (en) * 2020-01-31 2021-08-05 89Bio Ltd. Methods for promoting weight loss
TW202245824A (zh) * 2021-03-19 2022-12-01 大陸商廣東東陽光藥業有限公司 Fgf21多肽及其融合多肽的應用
CN113198002A (zh) * 2021-05-12 2021-08-03 上海交通大学医学院附属第九人民医院 一种用于治疗非酒精性脂肪肝的肝细胞因子bmp9
TW202317645A (zh) * 2021-07-05 2023-05-01 大陸商上海翰森生物醫藥科技有限公司 一種融合蛋白及其醫藥用途
CN113717269B (zh) * 2021-08-31 2022-04-19 赣江中药创新中心 一种重组的变体fgf21蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CN101974090B (zh) 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
EP1735340A2 (en) 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2008102923A1 (en) 2007-02-23 2008-08-28 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
CN103641919B (zh) 2007-05-30 2017-04-05 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP3260129A1 (en) 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
LT2393828T (lt) * 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
AR076541A1 (es) 2009-05-05 2011-06-22 Amgen Inc Mutantes de fgf21 y usos del mismo
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN102791730A (zh) * 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2661445A2 (en) 2011-01-04 2013-11-13 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
AU2014318579A1 (en) * 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR20170049320A (ko) 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
AU2017358289A1 (en) 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EA201992516A1 (ru) 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных

Also Published As

Publication number Publication date
CN108290937B (zh) 2022-03-08
EP3368554A4 (en) 2019-06-19
JP7453943B2 (ja) 2024-03-21
JP2021184727A (ja) 2021-12-09
JP2018534929A (ja) 2018-11-29
RU2018119141A (ru) 2019-12-02
US11142557B2 (en) 2021-10-12
RU2018119141A3 (es) 2020-03-24
BR112018008676A2 (pt) 2018-11-27
AU2021204115A1 (en) 2021-07-15
RU2741087C2 (ru) 2021-01-22
CA3003109A1 (en) 2017-05-04
AU2016346864B2 (en) 2021-03-18
ZA201802002B (en) 2019-05-29
HRP20201392T1 (hr) 2020-11-27
RS60725B1 (sr) 2020-09-30
WO2017074117A1 (en) 2017-05-04
ES2815540T3 (es) 2021-03-30
LT3368554T (lt) 2020-09-25
CN108290937A (zh) 2018-07-17
CY1123307T1 (el) 2021-12-31
JP7303629B2 (ja) 2023-07-05
DK3368554T3 (da) 2020-08-31
EP3368554B1 (en) 2020-08-05
AU2016346864A1 (en) 2018-05-10
HK1257375A1 (zh) 2019-10-18
KR20170049319A (ko) 2017-05-10
EP3744731A1 (en) 2020-12-02
US20180305428A1 (en) 2018-10-25
US20220002367A1 (en) 2022-01-06
HUE051036T2 (hu) 2021-01-28
EP3368554A1 (en) 2018-09-05
PT3368554T (pt) 2020-09-10
SI3368554T1 (sl) 2020-10-30

Similar Documents

Publication Publication Date Title
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
TN2015000053A1 (en) Fusion proteins for treating a metabolic syndrome
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MY187047A (en) Selective pyy compounds and uses thereof
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
WO2015051030A3 (en) Stabilized polypeptides and uses thereof
EA201492053A1 (ru) Белки фактора роста фибробластов 21
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
EP3278810A4 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
MX2016004257A (es) Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
MX2022013566A (es) Anticuerpo.
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EP4275751A3 (en) Improved naglu fusion protein formulation
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility
EA201691231A1 (ru) Фармацевтические лекарственные формы